IP Verse

Method For Diagnosing A Neurodegenerative Disease - EP3202914

The patent EP3202914 was granted to Hospital District OF Helsinki And Uusimaa on Jun 28, 2023. The application was originally filed on Aug 31, 2012 under application number EP16204118A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3202914

HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA
Application Number
EP16204118A
Filing Date
Aug 31, 2012
Status
Patent Maintained As Amended
May 26, 2023
Grant Date
Jun 28, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANJul 9, 2020CMS CAMERON MCKENNA NABARRO OLSWANGADMISSIBLE

Patent Citations (1) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONWO03000588

Non-Patent Literature (NPL) Citations (38) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CHIO ET AL., NEUROLOGY, (2008), vol. 70, pages 533 - 537-
DESCRIPTION- DEBOSE-BOYD ET AL., CELL, (1999), vol. 99, pages 703 - 712-
DESCRIPTION- HOLTTA-VUORI ET AL., MOLECULAR BIOLOGY OF THE CELL, (2002), vol. 13, pages 3107 - 3122-
DESCRIPTION- KOBAYASHI ET AL., AMERICAN JOURNAL OF HUMAN GENTICS, (2011), vol. 89, pages 121 - 130-
DESCRIPTION- KOHLER; MILSTEIN, NATURE, (1975), vol. 256, page 495-
DESCRIPTION- LAAKSOVIRTA ET AL., LANCET NEUROLOGY, (2010), vol. 9, pages 978 - 985-
DESCRIPTION- PEARSON ET AL., JOURNAL OF NEUROLOGY, (2011), vol. 258, pages 647 - 655-
DESCRIPTION- SHATUNOV ET AL., LANCET NEUROLOGY, (2010), vol. 9, pages 986 - 994-
DESCRIPTION- VAN DEERLIN ET AL., NATURE GENETICS, (2010), vol. 42, pages 234 - 239-
DESCRIPTION- WARNER ET AL., JOURNAL OF MEDICAL GENETICS, (1996), vol. 33, pages 1022 - 1026-
EXAMINATION- DONNELLY CHRISTOPHER J ET AL, "RNA Toxicity from the ALS/FTDC9ORF72Expansion Is Mitigated by Antisense Intervention", NEURON, CELL PRESS, US, (20131007), vol. 80, no. 2, doi:10.1016/J.NEURON.2013.10.015, ISSN 0896-6273, pages 415 - 428, XP028757398
EXAMINATION- JIANG JIE ET AL, "Gain of Toxicity from ALS/FTD-Linked Repeat Expansions inC9ORF72Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs", NEURON, CELL PRESS, US, (20160421), vol. 90, no. 3, doi:10.1016/J.NEURON.2016.04.006, ISSN 0896-6273, pages 535 - 550, XP029531466
EXAMINATION- YINGXIAO SHI ET AL, "Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons", NATURE MEDICINE, New York, (20180205), vol. 24, no. 3, doi:10.1038/nm.4490, ISSN 1078-8956, pages 313 - 325, XP055497485
EXAMINATION- C. LAGIER-TOURENNE ET AL, "Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (20131119), vol. 110, no. 47, doi:10.1073/pnas.1318835110, ISSN 0027-8424, pages E4530 - E4539, XP055228419
OPPOSITION- Balendra et al, (2018) Nat Rev Neurol 14(9):544-558-
OPPOSITION- CHAN JHP et al., 2006, Clinical and Experimental Pharmacology and Physiology, vol. 33, pages 533-540-
OPPOSITION- Dolzhenko et al., (2017) Genome Res. 27(11): 1895-1903-
OPPOSITION- Donnelly et al., (2013) Neuron 80(2) 415-428-
OPPOSITION- DONNELLY, "RNA Toxicity from the ALS/FTD C9ORF72Expansion Is Mitigated by Antisense Intervention" Neuron, 16 October 2013-
OPPOSITION- Extract from ClinicalTrials gov reporting on the Phase I clinical trial of BIIB078 (available from:https://clinicaltrials.gov/ct2/show/NCT03626012)-
OPPOSITION- Gossye et al, (2015) [Updated 2020 Dec 17]. In: Adam MP,Ardinger HH, Pagon RA, et aL, editors. Gene Reviews [Internet],Seattle (WA): University of Washington, Seattle; 1993-2021-
OPPOSITION- Jiang et al, (2016) Neuron 90(3):535-550-
OPPOSITION- JIANG, Jie et al., "Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC - Containing RNAs" Neuron, Vol. 90, 04 May 2016-
OPPOSITION- Kobayashi et al., (2011) Am. J. Human Genetics 89.121-130-
OPPOSITION- Laaksovirta et al. (2010), “Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study”, The Lancet Neurology, 9: 978-985-
OPPOSITION- Orr, H, T., (2011) Neuron 72:189-190-
OPPOSITION- PCT Request Form for PCT/GB2012/052140 dated 31 August 2012-
OPPOSITION- Press Release BIIB078, Globe Newswire, 28 March 2022-
OPPOSITION- Renton et al. (2011), “A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD”, Neuron, 72: 257-268-
OPPOSITION- Shatunov et al. (2010), “Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study”, The Lancet Neurology, 9: 986-994-
OPPOSITION- Signed assignment-
OPPOSITION- Todd, P. K. & Paulson, H.L. Ann. Neurol. 2010, 67(3): 291-300-
OPPOSITION- Waite et al., (2014) Neurobiology of Aging 35:1779.e5-1779.e13-
OPPOSITION- RENTON et al., "A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD", Neuron, (20110921), vol. 72, doi:10.1016/j.neuron.2011.09.010, pages 257 - 268, XP028322561
OPPOSITION- LAAKSOVIRTA et al., "Chromosome 9p21 in amyotrophic lateral sclerosis in Finland : a genome-wide association study", The Lancet Neurology, (20100831), vol. 9, doi:10.1016/S1474-4422(10)70184-8, pages 978 - 985, XP027599044
OPPOSITION- SHATUNOV et al., "Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study", The Lancet Neurology, (20110221), vol. 9, doi:10.1016/S1474-4422(10)70197-6, pages 986 - 994, XP027599045
SEARCH- LAAKSOVIRTA H ET AL, "Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study", LANCET NEUROLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 9, no. 10, doi:10.1016/S1474-4422(10)70184-8, ISSN 1474-4422, (20101001), pages 978 - 985, (20101001), XP027599044 [I] 1-10 * abstract * * the whole document *
SEARCH- ALEKSEY SHATUNOV ET AL, "Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study", LANCET NEUROL, (20101013), vol. 9, doi:10.1016/S1474-, pages 986 - 994, XP055050921 [I] 1-10 * abstract * * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents